Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Aug 21;16:17588359241266164. doi: 10.1177/17588359241266164

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s), 2024

This article is distributed under the terms of the Creative Commons Attribution 4.0 License (https://creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).

PMC Copyright notice

Figure 2. — Cost-effectiveness plane with base-case results.

Cost-effectiveness plane depicting the average discounted costs in € and quality-adjusted life-years (QALYs) of each strategy per patient. The black line represents the cost-effectiveness frontier. Note that the ctDNA-only strategy and combination strategies 1 and 2 are not on the cost-effectiveness frontier.

Current guideline: pT4, pMMR patients; ctDNA-only: ctDNA positive patients; Combination 1: pT4, pMMR patients and ctDNA positive, pMMR patients; Combination 2: pT4, pMMR patients and ctDNA-positive patients; Combination 3: pT4 patients and ctDNA-positive patients.